Thyroid cancer
Conditions
Interventions
Gold Standard:Needle capillary biopsy or pathological results after surgery
Index test:Eight novel thyroid hormone metabolites were tested in this study, including: iodothyronine, 3-iodothyronine, 3' -iodothyronine, 3-iodothyronine, 3, 5-diiodothyronine, 3', 5' -diiodothyroni
Sponsors
Xuzhou Central Hospital
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Thyroid cancer group: differentiated thyroid cancer patients aged 25-75 years with clinical surgical pathology; 2) Benign thyroid nodule group: patients with benign thyroid nodule aged 25-75 years with puncture cytology or clinical surgical pathology; 3) Healthy volunteers group: healthy volunteers aged 25-75 years with clinical ultrasound reports without thyroid nodule.
Exclusion criteria
Exclusion criteria: The individuals in DTC group are the patients with thyroid cancer diagnosed by biopsy. The serum samples were collected before surgery. The individuals will be excluded if they have the following conditions: (1) Abnormal thyroid function (Hyperthyroidism, hypothyroidism etc.); (2) Having a history of chemoradiotherapy; (3) Having other site tumors; (4) Having a history of surgery or blood transfusion in the past six months; (5) Having severe liver or kidney diseases; (6) Having metabolic diseases (Diabetes, Hyperlipidemia etc.); (6) Having immune system diseases (Lupus erythematosus, HIV etc.) The individuals in thyroid benign nodule group are the patients diagnosed by biopsy after FNA or surgery. The serum samples were collected before surgery or at the physical examination. The exclusion criteria were the same for patients in thyroid cancer group. The individuals in health control group are the volunteers without any thyroid tumor in ultrasonic detection. Additionally, the thyroid function and blood biochemical indexes of these volunteers were all in the normal range. The healthy female volunteers were also excluded from breast nodules and uterine fibroids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| diiodo-thyroxines;monoiodo-thyroxine;thyronine ;thyronamine;Sensitivity, SE;Specificity, SP;Positive predicative value, PPV; | — |
Secondary
| Measure | Time frame |
|---|---|
| Thyroxine ;triiodo-thyroxine; | — |
Countries
China
Contacts
Public ContactLiang Jun
Xuzhou Central Hospital
Outcome results
None listed